Revolver Therapeutics
Funding round (follow-on) · £572K
Peptide therapies targeting 'undruggable' cancer transcription factors; led by QantX with UKI2S and University of Bath following on.
About Revolver Therapeutics
Revolver Therapeutics is a company founded in 2023, now around 5 people. It has raised $732k in disclosed funding. FundFinder classes it as Health & Bio.
Founder: Mark Treherne (Co-founder and Chief Executive; repeat founder; previously AMPIKA LIMITED, Avilex Pharma ApS; University of Cambridge).
Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.
Want the latest on Revolver Therapeutics? Our research agent pulls the current
description, latest round and full investor base from public sources (about a minute).
Funding round (follow-on) · £572K · Jul 2026
- UK Innovation & Science Seed Fund (UKI2S) — Evergreen, government-backed pre-seed+ fund managed by Future Planet Capital. · cheques up to £1.5M